Effects of Immunomodulators on the Pharmacokinetics and Efficacy of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT-SC Induction and Maintenance Studies
Omoniyi J. Adedokun(Western University), William J. Sandborn(University of San Diego), Honghui Zhou(Janssen (United States)), Paul Rutgeerts(KU Leuven), Brian G. Feagan(Western University), Colleen Marano(Johnson & Johnson (United States)), Hongyan Zhang(Chinese University of Hong Kong), Zhenhua Xu(Hebei Medical University), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Joyce M. Ford(Springhouse), Walter Reinisch(Medical University of Vienna), Richard Strauß(Hennepin County Medical Center), Jewel Johanns(Johnson & Johnson (United States)), Hugh L. Davis(Springhouse)
Cited by 4
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k